The Claim
In adults with schizophrenia and metabolic syndrome on antipsychotics, adjunctive berberine at 600 mg/day for 12 weeks reduces glycated hemoglobin (HbA1c) by 0.09% compared to placebo, with a small-to-medium effect size (d=0.37), indicating modest improvement in long-term glucose control.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with schizophrenia and metabolic syndrome taking antipsychotic medication, taking 600 mg of berberine daily for 12 weeks lowers HbA1c by 0.09% compared to a placebo, showing a small-to-medium improvement in long-term blood sugar control.
See the scientific wording
In adults with schizophrenia and metabolic syndrome on antipsychotics, adjunctive berberine (600 mg/day for 12 weeks) reduces glycated hemoglobin (HbA1c) by 0.09% compared to placebo, with a small-to-medium effect size (d=0.37), indicating modest improvement in long-term glucose control.
Berberine triggers a cellular energy sensor called AMPK, which tells the liver to stop making excess sugar and tells muscles to take up more sugar from the blood, lowering long-term blood sugar levels.
What the research says
1 studyIn people with schizophrenia and metabolic syndrome, taking 600 mg of berberine daily for 12 weeks slightly lowered their blood sugar marker (HbA1c) compared to those who took a placebo — like a small but real improvement in long-term blood sugar control.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.